Two low molecular heparins are available in the United States: dalteparin and enoxaparin. Enoxaparin is low molecular weight heparin (LMWH) and was first approved for medical use in 1993 and is derived from heparin.

**FDA-approved Indications**

- Prophylaxis of deep vein thrombosis (DVT) in hip replacement surgery, abdominal surgery, knee replacement surgery, or medical patients with severely limited mobility during acute illness

- Inpatient management of acute deep vein thrombosis with or without pulmonary embolism

- Outpatient management of acute deep vein thrombosis without pulmonary embolism

- Prophylaxis of ischemic complications of Non-ST-elevation myocardial infarction (NSTEMI) and unstable angina

- Treatment of acute ST-segment elevation myocardial infarction managed medically or with the subsequent percutaneous coronary intervention

**Off-label Use**

- Primary prevention of venous thromboembolism (VTE)

- Treatment for prosthetic valve thrombosis in pregnancy

- Treatment for VTE in pregnancy

- Antiphospholipid antibody syndrome

- Arterial thromboembolism prophylaxis

- Cerebral thromboembolism

- Periprocedural anticoagulation

- Venous thromboembolism secondary to malignancy